ArticleNature immunology2026
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332
Abstract read
In one paragraph
Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.Nature communications · 2026Trial
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- Structural determination of the HIV-1 Variable Region 3 epitope of antibody 19b.Journal of virology · 2026Article
- Review
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.Nature immunology · 2026Article
- Better and closer glycan-independent anti-V3 antibodies to help HIV-1 vaccine.Nature immunology · 2026Article
- Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
37 authors.
Lutz Gieselmann *Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Andrew T DeLaitsch *Divison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0002-3458-3449
Malena Rohde *Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Caelan RadfordBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Johanna WorczinskiLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Anna AshurovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Elvin AhmadovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Judith A BurgerDepartment of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2880-3927
Sharvari DeshpandeVir Biotechnology, San Francisco, CA, USA.
Federico GiovannoniVir Biotechnology, Bellinzona, Switzerland.
Davide CortiVir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-5797-1364
Christoph KreerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-9140-9850
Meryem Seda ErcanogluLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Philipp SchommersLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-3375-6800
Ivelin S GeorgievVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
Anthony P WestDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0003-4213-5184
Jacqueline KnüferLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Ricarda StumpfLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Arne KroidlInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-3569-9176
Christof GeldmacherInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Lucas MagangaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Wiston WilliamMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Nyanda E NtinginyaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Michael HoelscherInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-7642-1835
Zhengrong YangDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Qing WeiDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Matthew B RenfrowDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Todd J GreenDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jan NovakDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-9211-6670
Marit J van GilsDepartment of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0003-3422-8161
Harry B GristickDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-0725-7138
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1267-3408
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Pamela J BjorkmanDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0002-2277-3990
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de.ORCID http://orcid.org/0000-0003-1376-1792
Funding
Stuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MCHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI WESLEY I. SUNDQUIST · 2022 to 2026
$34.4MDefining the mechanisms of HIV resistance to bNAbs in humansU01AI169385 · NIAID · ROCKEFELLER UNIVERSITY · PI Marina Caskey · 2022 to 2026
$7.8MDefining the impact of glycan-microdomains of the HIV-1 Env glycan shieldR01AI162236 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN, RENFROW, MATTHEW B · 2021 to 2025
$3.6MComplete mapping of immune selection from antibodies to HIVR01AI140891 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2019 to 2024
$2.4MDeutsche Forschungsgemeinschaft (German Research Foundation) CRC1279Deutsche Forschungsgemeinschaft (German Research Foundation) CRC1310EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC-stG639961Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AI140891Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) U01AI169385Gates Foundation INV-002143Gates Foundation INV-036842NIAID NIH HHS P01 AI100148NIAID NIH HHS R01 AI140891NIAID NIH HHS R01 AI162236NIAID NIH HHS U01 AI169385NIAID NIH HHS U54 AI170856
Abstract
Broadly neutralizing antibodies (bNAbs) against HIV-1 can suppress viremia in vivo and inform vaccine development. Here we characterized 007, a V3 glycan site bNAb exhibiting high levels of antiviral activity against multiclade pseudovirus panels. 007 targets an N332
Indexed as
Antibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsPolysaccharidesAIDS VaccinesAnimalsHumansImmunoglobulin GMiceAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin GPolysaccharides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.